Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & GamblefiledCriticalProcter & Gamble
Publication of PE37995A1publicationCriticalpatent/PE37995A1/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I DONDE: 1) R ES ALCANILO C1-C3, ALQUENILO C1-C3; 2) R` ES HIDROGENO, ALCANILO C1-C3, ALQUENILO C1-C3, ALQUILTIO C1-C3, ALCOXI C1-C3, TIOL, CIANO, HALOGENO; 3) R" ES HIDROGENO, METILO, ETILO, i-PROPILO; DE PREFERENCIA R ES METILO, ETILO; R' ES HIDROGENO, METILO, FLUOR; R" ES HIDROGENO, METILO. PUEDE SER UTIL EN EL TRATAMIENTO DE LA CONGESTION NASAL, GLAUCOMA Y DIARREA
PE1994257435A1993-12-171994-12-19Compuesto 5-(2-imidazolinilamino) benzimidazol util como agonista de adrenoreceptor alfa-2
PE37995A1
(es)